Researchers have developed an innovative nano-immune agonist that significantly improves immunotherapy outcomes for melanoma—a highly aggressive and hard-to-treat form of skin cancer.

A new study finds that fragments of tumor DNA in a patient's bloodstream could show that they are at high risk of a melanoma ...

Adjuvant treatment with dabrafenib and trametinib may be more effective than observation or adjuvant treatment with a PD-1 inhibitor in patients with stage IIIA melanoma.

Melanoma, the most dangerous form of skin cancer, often hides in plain sight. While many are vigilant about obvious changes ...

Study findings suggested that assessing ctDNA levels was as good or better at predicting recurrence than experimental tests ...

Droplet digital PCR measurements of circulating tumor (ct)DNA to assess minimal residual disease before the initiation of ...

Several patient-specific factors are associated with an increased rate of advanced melanoma at presentation, including age, gender, and race.

The clinical approach, epidemiology, diagnostic procedures, and management, along with followup of superficial spreading malignant melanoma are discussed. A 45-year-old Caucasian female presented ...

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a new study shows.

Although the tilsotolimod plus ipilimumab treatment did not meet its co-primary endpoint, these results are a valuable addition to the literature with respect to second-line treatment options in this ...